Richard Burr: “The Department strongly opposes House section 2711 because it would mandate that all EDCs be at no-cost.”

Without Orrin, we wouldn't have a generic drug industry.

I will tell you right now, Congress is going to require accountability in the new program.

The response was clear, FDA should be held accountable to its commitments.

I urge my colleagues, don't make this mistake. I know there is great pressure to do Build Back Better. But this is not the right bill.